MYC and non-Hodgkin lymphoma: The pharmacodynamic effect was reproduced on C1D15 after the third weekly dose of 30 mg enitociclib where MYC mRNA downregulation in patients with DH-DLBCL (n = 9, black lines) and on other MYC+ NHL (n = 3, colored lines) was 86.71% (range, 96.85%–50%) and 71.08% (range, 53.7%–86.9%), respectively.